{"id":66953,"date":"2026-06-01T14:51:32","date_gmt":"2026-06-01T06:51:32","guid":{"rendered":"https:\/\/flcube.com\/?p=66953"},"modified":"2026-06-01T14:51:33","modified_gmt":"2026-06-01T06:51:33","slug":"hanmi-pharm-secures-1-26-billion-deal-with-eli-lilly-for-glp-2-analog-sonefpeglutide-in-global-licensing-agreement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66953","title":{"rendered":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hanmi Pharm. Co., Ltd. (&#8220;Hanmi&#8221;)<\/strong> announced a strategic <strong>global licensing agreement<\/strong> with <strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> for the development, manufacturing, and commercialization of <strong>sonefpeglutide<\/strong>, Hanmi&#8217;s novel <strong>LAPS GLP-2 analog<\/strong> biologic drug candidate. Under the terms, Lilly acquires <strong>exclusive worldwide rights<\/strong> (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing <strong>global Phase 2 trial in Short Bowel Syndrome (SBS)<\/strong>. The deal includes a <strong>$75 million upfront payment<\/strong> and potential milestone payments totaling <strong>up to $1.185 billion<\/strong>, plus royalties on future sales.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Hanmi Pharm. Co., Ltd. and Eli Lilly (NYSE: LLY)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Sonefpeglutide (LAPS GLP-2 analog)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Hanmi&#8217;s proprietary <strong>LAPSCOVERY<\/strong> long-acting platform<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide exclusive rights to Lilly (excluding Korea)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>$75 million<\/strong><\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>$1.185 billion<\/strong> (clinical, regulatory, commercial)<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Royalties on net sales post-launch<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-amp-development-status\" class=\"wp-block-heading\">Asset Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Sonefpeglutide<\/strong> \u2013 novel <strong>GLP-2 analog<\/strong> leveraging Hanmi&#8217;s <strong>LAPSCOVERY<\/strong> long-acting platform technology<\/li>\n\n\n\n<li><strong>Primary Indication:<\/strong> <strong>Short Bowel Syndrome (SBS)<\/strong> \u2013 currently in global Phase 2 clinical development<\/li>\n\n\n\n<li><strong>Platform Advantage:<\/strong> LAPSCOVERY technology extends half-life and reduces dosing frequency compared to conventional GLP-2 analogs<\/li>\n\n\n\n<li><strong>Development Responsibilities:<\/strong><\/li>\n\n\n\n<li><strong>Hanmi<\/strong>: Complete ongoing global Phase 2 SBS trial<\/li>\n\n\n\n<li><strong>Lilly<\/strong>: Explore additional clinical indications based on existing nonclinical and clinical data<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> GLP-2 analogs promote intestinal mucosal growth and nutrient absorption, addressing unmet needs in gastrointestinal disorders<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership leverages complementary strengths between the Korean innovator and global pharmaceutical leader:<\/p>\n\n\n\n<h3 id=\"h-for-hanmi\" class=\"wp-block-heading\">For Hanmi:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion<\/strong>: Immediate $75 million strengthens balance sheet for other pipeline programs<\/li>\n\n\n\n<li><strong>Global Development Expertise<\/strong>: Access to Lilly&#8217;s extensive clinical development and regulatory capabilities<\/li>\n\n\n\n<li><strong>Commercial Scale<\/strong>: Partnership with established leader in metabolic diseases ensures optimal market penetration<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Transfers late-stage development costs and commercialization risks to Lilly<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-lilly\" class=\"wp-block-heading\">For Lilly:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Expansion<\/strong>: Adds novel GLP-2 mechanism to complement existing metabolic disease portfolio<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Gains access to Hanmi&#8217;s proprietary LAPSCOVERY long-acting technology<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Opportunity to establish leadership in underserved gastrointestinal therapeutic areas<\/li>\n\n\n\n<li><strong>Strategic Optionality<\/strong>: Rights to explore multiple indications beyond initial SBS focus<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This landmark agreement validates our LAPSCOVERY platform and sonefpeglutide&#8217;s potential to address significant unmet medical needs,&#8221; said Dr. Kwon Seung-hwan, Chief Executive Officer of Hanmi Pharm. &#8220;Partnering with Lilly, a global leader in metabolic diseases, ensures that sonefpeglutide will reach patients worldwide with optimal development resources and commercial expertise.&#8221;<\/p>\n\n\n\n<h2 id=\"h-financial-impact-amp-industry-context\" class=\"wp-block-heading\">Financial Impact &amp; Industry Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>$1.26 billion total deal value<\/strong> represents one of the largest outbound licensing agreements from a Korean biotech company:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Milestone Structure<\/strong>: Payments tied to clinical progress, regulatory approvals across major markets (US, EU, Japan), and commercial sales thresholds<\/li>\n\n\n\n<li><strong>Royalty Terms<\/strong>: Expected mid-to-high single-digit royalty rates on net sales<\/li>\n\n\n\n<li><strong>Market Potential<\/strong>: GLP-2 analog market projected to reach <strong>$3\u20135 billion annually<\/strong> by 2030, driven by SBS and potential expansion into inflammatory bowel disease (IBD) and other gastrointestinal disorders<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Sonefpeglutide competes with Takeda&#8217;s <strong>teduglutide (Gattex\/Revestive)<\/strong>, the current standard of care for SBS<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view the deal as transformative for Hanmi, providing substantial non-dilutive funding to advance its broader pipeline while establishing a strategic partnership with a top-tier global pharmaceutical company.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, clinical development plans, and financial projections. Actual results may differ due to clinical trial outcomes, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hanmi Pharm. Co., Ltd. (&#8220;Hanmi&#8221;) announced a strategic global licensing agreement with Eli Lilly (NYSE:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,199,261,911,86],"class_list":["post-66953","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-eli-lilly","tag-hanmi-pharmaceutical","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hanmi Pharm. Co., Ltd. (&quot;Hanmi&quot;) announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi&#039;s novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66953\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement\" \/>\n<meta property=\"og:description\" content=\"Hanmi Pharm. Co., Ltd. (&quot;Hanmi&quot;) announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi&#039;s novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66953\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:51:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T06:51:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement\",\"datePublished\":\"2026-06-01T06:51:32+00:00\",\"dateModified\":\"2026-06-01T06:51:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"Eli Lilly\",\"Hanmi Pharmaceutical\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66953#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66953\",\"name\":\"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T06:51:32+00:00\",\"dateModified\":\"2026-06-01T06:51:33+00:00\",\"description\":\"Hanmi Pharm. Co., Ltd. (\\\"Hanmi\\\") announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi's novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66953\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66953#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement - Insight, China&#039;s Pharmaceutical Industry","description":"Hanmi Pharm. Co., Ltd. (\"Hanmi\") announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi's novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66953","og_locale":"en_US","og_type":"article","og_title":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement","og_description":"Hanmi Pharm. Co., Ltd. (\"Hanmi\") announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi's novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.","og_url":"https:\/\/flcube.com\/?p=66953","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:51:32+00:00","article_modified_time":"2026-06-01T06:51:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66953#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66953"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement","datePublished":"2026-06-01T06:51:32+00:00","dateModified":"2026-06-01T06:51:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66953"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","Eli Lilly","Hanmi Pharmaceutical","NYSE: LLY","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66953#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66953","url":"https:\/\/flcube.com\/?p=66953","name":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T06:51:32+00:00","dateModified":"2026-06-01T06:51:33+00:00","description":"Hanmi Pharm. Co., Ltd. (\"Hanmi\") announced a strategic global licensing agreement with Eli Lilly (NYSE: LLY) for the development, manufacturing, and commercialization of sonefpeglutide, Hanmi's novel LAPS GLP-2 analog biologic drug candidate. Under the terms, Lilly acquires exclusive worldwide rights (excluding Korea) to the asset, while Hanmi retains responsibility for completing its ongoing global Phase 2 trial in Short Bowel Syndrome (SBS). The deal includes a $75 million upfront payment and potential milestone payments totaling up to $1.185 billion, plus royalties on future sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66953#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66953"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66953#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66953"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66953\/revisions"}],"predecessor-version":[{"id":66954,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66953\/revisions\/66954"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}